Literature DB >> 9427720

Suppression of cell proliferation and the expression of a bcr-abl fusion gene and apoptotic cell death in a new human chronic myelogenous leukemia cell line, KT-1, by interferon-alpha.

K Yanagisawa1, H Yamauchi, M Kaneko, H Kohno, H Hasegawa, S Fujita.   

Abstract

A new human leukemia cell line, KT-1, was established from a patient in the blastic crisis phase of chronic myelogenous leukemia (CML). This cell line had a positive reaction for intracytoplasmic myeloperoxidase and two Philadelphia chromosomes (Ph1) [t(9;22)(q34;q11)] and lacked normal copies of chromosomes 9 and 22. Molecular characterization of the breakpoint in the t(9;22)(q34;q11) showed that KT-1 had a bcr-2/abl-2 splice junction. When the KT-1 cells were cultured with interferon (IFN)-alpha or IFN-gamma, the growth of the cells were dose-dependently suppressed. IFN-alpha and IFN-gamma exerted synergistic suppressive effects on the growth of KT-1 cells. Furthermore, IFN-alpha suppressed the expression of the bcr-abl fusion gene in KT-1 cells, and induced G1 cell-cycle arrest and apoptotic cell death. The KT-1 cell line should be a valuable tool for studying the molecular mechanism of the suppression of Ph1 clone cells from CML by IFN.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9427720

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  12 in total

1.  Ubp43 regulates BCR-ABL leukemogenesis via the type 1 interferon receptor signaling.

Authors:  Ming Yan; Jiann-Kae Luo; Kenneth J Ritchie; Ikuya Sakai; Kasuto Takeuchi; Ruibao Ren; Dong-Er Zhang
Journal:  Blood       Date:  2007-03-20       Impact factor: 22.113

2.  Establishment and characterization of A novel Philadelphia-chromosome positive chronic myeloid leukemia cell line, TCC-S, expressing P210 and P190 BCR/ABL transcripts but missing normal ABL gene.

Authors:  Phan Nguyen Thanh Van; Phan Thi Xinh; Yasuhiko Kano; Katsushi Tokunaga; Yuko Sato
Journal:  Hum Cell       Date:  2005-03       Impact factor: 4.174

3.  Bcr-abl signals to desensitize chronic myeloid leukemia cells to IFNα via accelerating the degradation of its receptor.

Authors:  Sabyasachi Bhattacharya; Hui Zheng; Christos Tzimas; Martin Carroll; Darren P Baker; Serge Y Fuchs
Journal:  Blood       Date:  2011-08-05       Impact factor: 22.113

4.  Sirtuin 2-mediated deacetylation of cyclin-dependent kinase 9 promotes STAT1 signaling in type I interferon responses.

Authors:  Ewa M Kosciuczuk; Swarna Mehrotra; Diana Saleiro; Barbara Kroczynska; Beata Majchrzak-Kita; Pawel Lisowski; Caroline Driehaus; Anna Rogalska; Acara Turner; Thomas Lienhoop; David Gius; Eleanor N Fish; Athanassios Vassilopoulos; Leonidas C Platanias
Journal:  J Biol Chem       Date:  2018-11-28       Impact factor: 5.157

5.  IFN-γ-inducible antiviral responses require ULK1-mediated activation of MLK3 and ERK5.

Authors:  Diana Saleiro; Gavin T Blyth; Ewa M Kosciuczuk; Patrick A Ozark; Beata Majchrzak-Kita; Ahmet D Arslan; Mariafausta Fischietti; Neha K Reddy; Curt M Horvath; Roger J Davis; Eleanor N Fish; Leonidas C Platanias
Journal:  Sci Signal       Date:  2018-11-20       Impact factor: 8.192

6.  Activation of protein kinase C{eta} by type I interferons.

Authors:  Amanda J Redig; Antonella Sassano; Beata Majchrzak-Kita; Efstratios Katsoulidis; Hui Liu; Jessica K Altman; Eleanor N Fish; Amittha Wickrema; Leonidas C Platanias
Journal:  J Biol Chem       Date:  2009-02-11       Impact factor: 5.157

7.  Activation of the p38 Map kinase pathway is essential for the antileukemic effects of dasatinib.

Authors:  Disha Dumka; Poonam Puri; Nathalie Carayol; Crystal Lumby; Harikrishnan Balachandran; Katja Schuster; Amit K Verma; Lance S Terada; Leonidas C Platanias; Simrit Parmar
Journal:  Leuk Lymphoma       Date:  2009-12

8.  Immunomodulatory and direct activities of ropeginterferon alfa-2b on cancer cells in mouse models of leukemia.

Authors:  Kazuki Sakatoku; Yasuhiro Nakashima; Joji Nagasaki; Mitsutaka Nishimoto; Asao Hirose; Mika Nakamae; Hideo Koh; Masayuki Hino; Hirohisa Nakamae
Journal:  Cancer Sci       Date:  2022-05-02       Impact factor: 6.518

Review 9.  Re-emergence of interferon-α in the treatment of chronic myeloid leukemia.

Authors:  M Talpaz; R Hehlmann; A Quintás-Cardama; J Mercer; J Cortes
Journal:  Leukemia       Date:  2012-11-07       Impact factor: 11.528

10.  Inhibition of euchromatic histone methyltransferase 1 and 2 sensitizes chronic myeloid leukemia cells to interferon treatment.

Authors:  Sheng Wei Loh; Wei Lun Ng; Kok Siong Yeo; Yat-Yuen Lim; Chee-Kwee Ea
Journal:  PLoS One       Date:  2014-07-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.